Novadaq's OPTTX for AMD (age-related macular degeneration):
This article was originally published in Clinica
Novadaq Technologies has CE-marked for sale in Europe what it claims is the first commercially available tool that can diagnose, treat and manage wet age-related macular degeneration (AMD) in a single device. The OPTTX system produces ultra high-speed indocyanine green angiograms and facilitates the identification of choroidal feeder vessels (FVs). It also allows the physician to view a real-time angiogram, in which a treatment laser is able to track and fire precisely while the FV is visible. It then enables the physician to immediately confirm the effectiveness of the treatment. Conventional feeder vessel therapy for the condition uses two medical devices, one for imaging, and the second for treatment, explained the Toronto, Canada firm. Novadaq is conducting a limited launch of the OPTTX system, and plans full commercialisation in the second quarter of 2007.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.